Preclinical studies have shown that the agonistic anti-CD40 antibody CP-870,893 reprograms TAMs into M1-like effector cells with enhanced antigen-presenting capacity, thereby restoring tumor immune surveillance and promoting tumor regression in murine models [426]. Here, CD40 is linked to neoplasm.